FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2567204735> ?p ?o ?g. }

• W2567204735 endingPage "1118" @default.
• W2567204735 startingPage "1118" @default.
• W2567204735 abstract "Abstract Amplification and point mutation in MET are well-characterized oncogenic drivers that confer susceptibility to MET inhibitors, such as crizotinib, particularly in non-small cell lung cancer. Splice site alterations at exon 14 of the MET (METex14) gene result in exon skipping and MET activation through loss of a DpYR motif (Y1003) that recruits the ubiquitin ligase CBL, targeting MET for degradation. METex14 skipping mutations have primarily been detected in lung adenocarcinoma, occurring in ∼3% of cases, but also in neuroblastoma and gastric cancer cell lines. 17 distinct variants have been characterized, however, their full diversity and prevalence across tumor types is unknown. Most importantly, it is unknown whether these mutations confer clinical susceptibility to targeted therapy with multiple MET inhibitors. We report here analysis of 29,714 cancer genomes to identify 168 harboring METex14 splicing mutations, including 101 distinct genomic variants. They are detected most frequently in lung adenocarcinoma (3.1%, 104/3360), but also in other lung neoplasms (2.0%, 40/2022), brain glioma (0.5%, 6/1312), tumors of unknown primary origin (0.4%, 11/2516), and other tumor types (0.03% 7/20504). Lung malignancies with these mutations do not have other characteristic driver mutations, and have a distinct profile of co-occurring mutations, supporting the role of METex14 skipping as the primary drivers of oncogenesis in these specimens. Most importantly, patients with tumors harboring these mutations demonstrate durable response to anti-MET targeted therapy, in several tumor types. These data demonstrate that METex14 splicing mutations define a distinct class of tumors that are responsive to targeted therapy. The diversity of these variants indicates that diagnostic testing via massively parallel sequencing is necessary for detection in a clinical setting. The data also suggest that thousands of cancer genome profiles will be required to discover non-coding cancer drivers with degenerate genomic signatures. Citation Format: Garrett M. Frampton, Siraj Ali, Juliann Chmielecki, Mark Rosenzweig, Timothy Brennan, Zachary Chalmers, Julia Elvin, Alex Fichtenholtz, Kyle Gowan, Joel Greenbowe, Adrienne Johnson, Lily Khaira, Doron Lipson, Caitlin McMahon, Steven Roels, Roman Yelensky, Deborah Morosini, Philip Stephens, Vincent Miller. Activation of MET via diverse exon 14 skipping mutations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1118. doi:10.1158/1538-7445.AM2015-1118" @default.
• W2567204735 created "2017-01-06" @default.
• W2567204735 creator A5000119117 @default.
• W2567204735 creator A5003901411 @default.
• W2567204735 creator A5011609796 @default.
• W2567204735 creator A5027708109 @default.
• W2567204735 creator A5029183165 @default.
• W2567204735 creator A5033808702 @default.
• W2567204735 creator A5035120516 @default.
• W2567204735 creator A5036271179 @default.
• W2567204735 creator A5050762288 @default.
• W2567204735 creator A5051541097 @default.
• W2567204735 creator A5051868448 @default.
• W2567204735 creator A5056903351 @default.
• W2567204735 creator A5062006821 @default.
• W2567204735 creator A5063661642 @default.
• W2567204735 creator A5071731260 @default.
• W2567204735 creator A5073082179 @default.
• W2567204735 creator A5078397910 @default.
• W2567204735 creator A5079433880 @default.
• W2567204735 creator A5088809839 @default.
• W2567204735 date "2015-08-01" @default.
• W2567204735 modified "2023-09-25" @default.
• W2567204735 title "Abstract 1118: Activation of MET via diverse exon 14 skipping mutations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors" @default.
• W2567204735 doi "https://doi.org/10.1158/1538-7445.am2015-1118" @default.
• W2567204735 hasPublicationYear "2015" @default.
• W2567204735 type Work @default.
• W2567204735 sameAs 2567204735 @default.
• W2567204735 citedByCount "9" @default.
• W2567204735 countsByYear W25672047352019 @default.
• W2567204735 countsByYear W25672047352020 @default.
• W2567204735 countsByYear W25672047352021 @default.
• W2567204735 countsByYear W25672047352022 @default.
• W2567204735 crossrefType "journal-article" @default.
• W2567204735 hasAuthorship W2567204735A5000119117 @default.
• W2567204735 hasAuthorship W2567204735A5003901411 @default.
• W2567204735 hasAuthorship W2567204735A5011609796 @default.
• W2567204735 hasAuthorship W2567204735A5027708109 @default.
• W2567204735 hasAuthorship W2567204735A5029183165 @default.
• W2567204735 hasAuthorship W2567204735A5033808702 @default.
• W2567204735 hasAuthorship W2567204735A5035120516 @default.
• W2567204735 hasAuthorship W2567204735A5036271179 @default.
• W2567204735 hasAuthorship W2567204735A5050762288 @default.
• W2567204735 hasAuthorship W2567204735A5051541097 @default.
• W2567204735 hasAuthorship W2567204735A5051868448 @default.
• W2567204735 hasAuthorship W2567204735A5056903351 @default.
• W2567204735 hasAuthorship W2567204735A5062006821 @default.
• W2567204735 hasAuthorship W2567204735A5063661642 @default.
• W2567204735 hasAuthorship W2567204735A5071731260 @default.
• W2567204735 hasAuthorship W2567204735A5073082179 @default.
• W2567204735 hasAuthorship W2567204735A5078397910 @default.
• W2567204735 hasAuthorship W2567204735A5079433880 @default.
• W2567204735 hasAuthorship W2567204735A5088809839 @default.
• W2567204735 hasConcept C104317684 @default.
• W2567204735 hasConcept C121608353 @default.
• W2567204735 hasConcept C142724271 @default.
• W2567204735 hasConcept C176944494 @default.
• W2567204735 hasConcept C194583182 @default.
• W2567204735 hasConcept C2776232967 @default.
• W2567204735 hasConcept C2776256026 @default.
• W2567204735 hasConcept C2778776201 @default.
• W2567204735 hasConcept C2779422266 @default.
• W2567204735 hasConcept C2781182431 @default.
• W2567204735 hasConcept C2781230642 @default.
• W2567204735 hasConcept C36823959 @default.
• W2567204735 hasConcept C501734568 @default.
• W2567204735 hasConcept C502942594 @default.
• W2567204735 hasConcept C54355233 @default.
• W2567204735 hasConcept C555283112 @default.
• W2567204735 hasConcept C71924100 @default.
• W2567204735 hasConcept C86803240 @default.
• W2567204735 hasConceptScore W2567204735C104317684 @default.
• W2567204735 hasConceptScore W2567204735C121608353 @default.
• W2567204735 hasConceptScore W2567204735C142724271 @default.
• W2567204735 hasConceptScore W2567204735C176944494 @default.
• W2567204735 hasConceptScore W2567204735C194583182 @default.
• W2567204735 hasConceptScore W2567204735C2776232967 @default.
• W2567204735 hasConceptScore W2567204735C2776256026 @default.
• W2567204735 hasConceptScore W2567204735C2778776201 @default.
• W2567204735 hasConceptScore W2567204735C2779422266 @default.
• W2567204735 hasConceptScore W2567204735C2781182431 @default.
• W2567204735 hasConceptScore W2567204735C2781230642 @default.
• W2567204735 hasConceptScore W2567204735C36823959 @default.
• W2567204735 hasConceptScore W2567204735C501734568 @default.
• W2567204735 hasConceptScore W2567204735C502942594 @default.
• W2567204735 hasConceptScore W2567204735C54355233 @default.
• W2567204735 hasConceptScore W2567204735C555283112 @default.
• W2567204735 hasConceptScore W2567204735C71924100 @default.
• W2567204735 hasConceptScore W2567204735C86803240 @default.
• W2567204735 hasIssue "15_Supplement" @default.
• W2567204735 hasLocation W25672047351 @default.
• W2567204735 hasOpenAccess W2567204735 @default.
• W2567204735 hasPrimaryLocation W25672047351 @default.
• W2567204735 hasRelatedWork W1947227086 @default.
• W2567204735 hasRelatedWork W2045514639 @default.
• W2567204735 hasRelatedWork W2058332209 @default.
• W2567204735 hasRelatedWork W2140698435 @default.
• W2567204735 hasRelatedWork W2167075467 @default.

• next